{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T23:40:54Z","timestamp":1775086854811,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Key Scientific Instruments and Equipment Development","award":["2011YQ03013407"],"award-info":[{"award-number":["2011YQ03013407"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.leukres.2018.07.012","type":"journal-article","created":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T23:53:45Z","timestamp":1532735625000},"page":"12-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["A seven-color panel including CD34 and TdT could be applied in >97% patients with T cell lymphoblastic leukemia for minimal residual disease detection independent of the initial phenotype"],"prefix":"10.1016","volume":"72","author":[{"given":"Ya-Zhe","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7131-0522","authenticated-orcid":false,"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le-Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling-Ling","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Ying","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Zhen","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7749-8087","authenticated-orcid":false,"given":"Xiao-Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Rong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2018.07.012_bib0005","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1182\/blood-2003-05-1495","article-title":"Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T- cell malignancies: results of EORTC studies 58881 and 58951","volume":"103","author":"Cav\u00e9","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.07.012_bib0010","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/leu.2009.250","article-title":"Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia","volume":"24","author":"Conter","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.07.012_bib0015","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)10295-1","article-title":"Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia","volume":"351","author":"Coustan-Smith","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2018.07.012_bib0020","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/blood-2008-01-132837","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children\u2019s Oncology Group Study","volume":"111","author":"Borowitz","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.07.012_bib0025","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1182\/blood.V99.6.1952","article-title":"Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia","volume":"99","author":"Dworzak","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.07.012_bib0030","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/leu.2009.268","article-title":"Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18\u201320 September, 2008","volume":"24","author":"Br\u00fcggemann","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.07.012_bib0035","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/blood-2006-01-0066","article-title":"A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome","volume":"108","author":"Coustan-Smith","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.07.012_bib0040","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1200\/JCO.2013.52.2425","volume":"32","author":"Ribera","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.07.012_bib0045","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.1200\/JCO.2008.20.8934","article-title":"Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow","volume":"27","author":"Basso","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.07.012_bib0050","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1182\/blood.V96.8.2691","article-title":"Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia","volume":"96","author":"Coustan-Smith","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.07.012_bib0055","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1182\/blood-2002-08-2613","article-title":"Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotpic evaluation has high clinical value","volume":"101","author":"Vidriales","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.07.012_bib0060","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1046\/j.1365-2141.2003.03974.x","article-title":"Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia","volume":"120","author":"Krampera","year":"2003","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2018.07.012_bib0065","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev.immunol.24.021605.090612","article-title":"Development of human lymphoid cells","volume":"24","author":"Blom","year":"2006","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.leukres.2018.07.012_bib0070","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.hoc.2009.07.010","article-title":"Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia","volume":"23","author":"Campana","year":"2009","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.leukres.2018.07.012_bib0075","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/sj.leu.2401741","article-title":"BIOMED-1 concerted action report: flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL)","volume":"14","author":"Porwit-MacDonald","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.07.012_bib0080","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0145-2126(81)90002-3","article-title":"Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukaemia","volume":"5","author":"Bradstock","year":"1981","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2018.07.012_bib0085","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.4049\/jimmunol.135.5.3144","article-title":"Human bone marrow cells positive for terminal deoxynucleotidyl transferase (TdT), HLA-DR, and a T cell marker may represent prothymocytes","volume":"135","author":"van Dongen","year":"1985","journal-title":"J. Immunol."},{"key":"10.1016\/j.leukres.2018.07.012_bib0090","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4049\/jimmunol.138.2.648","article-title":"The cytoplasmic expression of CD3 antigens in normal and malignant cells of the T lymphoid lineage","volume":"138","author":"Campana","year":"1987","journal-title":"J. Immunol."},{"key":"10.1016\/j.leukres.2018.07.012_bib0095","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1182\/blood.V77.12.2591.2591","article-title":"Identification and comparison of CD34-positive cells and their subpopulations from normal peripheral blood and bone marrow using multicolor flow cytometry","volume":"77","author":"Bender","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.07.012_bib0100","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/cyto.b.20511","article-title":"Immaturity associated antigens are lost during induction for T cell lymphoblastic leukemia: implications for minimal residual disease detection","volume":"78","author":"Roshal","year":"2010","journal-title":"Cytom. B Clin. Cytom."},{"key":"10.1016\/j.leukres.2018.07.012_bib0105","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the International ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.07.012_bib0110","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","article-title":"Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial","volume":"109","author":"Moorman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.07.012_bib0115","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/ijlh.12711","article-title":"The clinical significance of monitoring the expression of the SIL-TAL1 fusion gene in T-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation","volume":"39","author":"Zhao","year":"2017","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.leukres.2018.07.012_bib0120","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe against cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.07.012_bib0125","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u2018real- time\u2019 quantitative reverse- transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program","volume":"17","author":"Beillard","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.07.012_bib0130","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1200\/JCO.2008.21.1318","article-title":"Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children\u2019s oncology group","volume":"27","author":"Coustan-Smith","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.07.012_bib0135","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/sj.leu.2403303","article-title":"CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease","volume":"18","author":"Dworzak","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.07.012_bib0140","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/cyto.b.20408","article-title":"Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells","volume":"74","author":"Gaipa","year":"2008","journal-title":"Cytom. B Clin. Cytom."},{"key":"10.1016\/j.leukres.2018.07.012_bib0145","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/MPH.0b013e318161a28f","article-title":"Effects of prednisolone on specifically expressed genes in pediatric acute B-lymphoblastic leukemia","volume":"30","author":"Akiyama","year":"2008","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2018.07.012_bib0150","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/S0140-6736(98)04058-6","article-title":"Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood","volume":"352","author":"van Dongen","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2018.07.012_bib0155","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1056\/NEJM199808273390904","article-title":"European organization for research and treatment of cancer\u2013childhood leukemia cooperative group","volume":"339","author":"Cav\u00e9","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2018.07.012_bib0160","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/sj.leu.2403283","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse","volume":"18","author":"Coustan-Smith","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.07.012_bib0165","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1182\/blood-2011-09-377713","article-title":"Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.07.012_bib0170","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1200\/JCO.2013.52.2425","volume":"32","author":"Ribera","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2018.07.012_bib0175","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12887-015-0390-z","article-title":"Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China","volume":"15","author":"Wei","year":"2015","journal-title":"BMC Pediatr."},{"key":"10.1016\/j.leukres.2018.07.012_bib0180","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1182\/blood-2015-03-580027","article-title":"Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies","volume":"125","author":"van Dongen","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.07.012_bib0185","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.4103\/0366-6999.161365","article-title":"Outcomes of adults with acute lymphoblastic leukemia after autologous hematopoietic stem cell transplantation and the significance of pretransplantation minimal residual disease: analysis from a single center of China","volume":"128","author":"Ding","year":"2015","journal-title":"Chin. Med. J. (Engl.)"},{"issue":"February","key":"10.1016\/j.leukres.2018.07.012_bib0190","article-title":"Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group (COG)","author":"Gupta","year":"2018","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.leukres.2018.07.012_bib0195","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1200\/JCO.1998.16.12.3774","article-title":"Prognositc value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia","volume":"16","author":"Ciudad","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2018.07.012_bib0200","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.1999.01300.x","article-title":"Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: detection in remission marrow predicts outcome","volume":"105","author":"Griesinger","year":"1999","journal-title":"Br. J. Haematol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618301565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618301565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:47:55Z","timestamp":1693788475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212618301565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":40,"alternative-id":["S0145212618301565"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2018.07.012","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A seven-color panel including CD34 and TdT could be applied in >97% patients with T cell lymphoblastic leukemia for minimal residual disease detection independent of the initial phenotype","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2018.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}